ducovest

SNY:NYE-Sanofi American Depositary Shares (Each repstg one-half of one) (USD)

EQUITY | Drug Manufacturers - General | New York Stock Exchange

Last Closing

USD 48.73

Change

0.00 (0.00)%

Market Cap

USD 100.27B

Volume

2.22M

Analyst Target

USD 56.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Company Website : http://www.sanofi.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

 USD 202.63B
AMGN Amgen Inc

N/A

 USD 141.18B
GILD Gilead Sciences Inc

N/A

 USD 115.13B
BIIB Biogen Inc

N/A

 USD 22.16B
GRFS Grifols SA ADR

N/A

 USD 7.13B
AMRN Amarin Corporation PLC

N/A

 USD 0.18B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

 USD 0.02B
SCLX Scilex Holding Company

N/A

 N/A
SCLXW Scilex Holding Company

N/A

 N/A

ETFs Containing SNY

HVAX:CA 4.85 % 0.00 %

N/A

 N/A
PPH VanEck Pharmaceutical ETF 4.66 % 0.36 %

N/A

 USD 0.60B
PINK Simplify Exchange Traded .. 4.63 % 0.00 %

N/A

 USD 0.15B
GMOI The 2023 ETF Series Trust.. 2.51 % 0.00 %

N/A

 USD 0.04B
SEUC:SW SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

N/A

 USD 0.87B
ADRD 0.00 % 0.26 %

N/A

 N/A
ADRU 0.00 % 0.30 %

N/A

 N/A
EUR:CA 0.00 % 0.66 %

N/A

 N/A
HIG-U:CA 0.00 % 0.00 %

N/A

 N/A
SANE 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.01% 70% C- 47% F
Dividend Return 4.10% 100% F 67% D+
Total Return 2.09% 80% B- 49% F
Trailing 12 Months  
Capital Gain -2.01% 70% C- 47% F
Dividend Return 4.10% 100% F 67% D+
Total Return 2.09% 80% B- 49% F
Trailing 5 Years  
Capital Gain -2.91% 57% F 51% F
Dividend Return 19.21% 80% B- 75% C
Total Return 16.30% 57% F 55% F
Average Annual (5 Year Horizon)  
Capital Gain 1.16% 80% B- 42% F
Dividend Return 4.88% 80% B- 49% F
Total Return 3.71% 100% F 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 11.26% 100% F 87% B+
Risk Adjusted Return 43.32% 80% B- 72% C
Market Capitalization 100.27B 75% C 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.70 86% 38%
Price/Book Ratio 1.57 63% 58%
Price / Cash Flow Ratio 11.66 88% 26%
Price/Free Cash Flow Ratio 14.54 50% 27%
Management Effectiveness  
Return on Equity 5.82% 63% 68%
Return on Invested Capital 6.81% 50% 71%
Return on Assets 4.16% 50% 82%
Debt to Equity Ratio 19.38% 100% 62%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.